CSIMarket
 
Trinity Biotech Plc  (NASDAQ: TRIB)
 
Price: $9.4100 $-0.19 -1.979%
Day's High: $9.84000015258789 Week Perf: -4.66 %
Day's Low: $ 9.24 30 Day Perf: -19.16 %
Volume (M): 11,116 52 Wk High: $ 107.50
Volume (M$): $ 0 52 Wk Avg: $2.03
Open: $9.67 52 Wk Low: $0.30



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 380
 Revenues (TTM) (Millions $) 44
 Net Income (TTM) (Millions $) -37
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Trinity Biotech Plc is a leading global provider of medical diagnostic testing solutions.
The company is headquartered in Bray, Ireland, and has operations in over 100 countries.
Trinity Biotech offers a broad range of medical diagnostic products, including tests for infectious diseases, sexually transmitted infections, autoimmune disorders, and blood disorders.
The company's flagship products include the Uni-GoldTM HIV rapid test, the CaptiaTM Lyme IgG and IgM tests, and the EUROBIOLINE Autoimmune product line.
Trinity Biotech has a strong focus on research and development, with a team of scientists continually developing new diagnostic products to meet the evolving needs of the healthcare industry.
The company has a number of patents and patent applications for its diagnostic technologies.
In addition to its diagnostic products, Trinity Biotech offers a range of services to support its customers, including training, technical support, and laboratory services.
The company has a global network of distribution partners and operates manufacturing facilities in Ireland, the United States, and Italy.
Trinity Biotech has been listed on the NASDAQ stock exchange since 1992.


   Company Address: IDA Business Park Bray, County Wicklow 0
   Company Phone Number: 1276 9800   Stock Exchange / Ticker: NASDAQ TRIB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

A New Dawn for Maternal Health Trinity Biotechs PreClara Test Set to Transform Preeclampsia Management,

Published Thu, Aug 14 2025 1:14 PM UTC

In an important stride for maternal health, Trinity Biotech has secured regulatory approval from the New York State Department of Health (NYSDOH) to begin its PreClara Preeclampsia Testing Service. Set to launch in the third quarter of 2025, this innovative biomarker test aims to enhance the monitoring and management of hypertensive disorders during pregnancy, a condition th...

Financing Agreement

Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan

Published Tue, Dec 24 2024 1:34 PM UTC

Trinity Biotechns Strategic Financial Maneuvers and Manufacturing Transition: Paving the Way for Market LeadershipIn a bold move to enhance operational efficiency and fortify its financial standing, Trinity Biotech plc (Nasdaq: TRIB), a biotechnology company based in Dublin, has taken significant steps towards executing its Comprehensive Transformation Plan. The company, fo...

Clinical Study

Advances in HIV Diagnostics Trinity Biotechs Strategic Shift to Offshore Manufacturing Following WHO Approval

Published Wed, Dec 18 2024 4:01 PM UTC

Trinity Biotech plc, a biotechnology company based in Dublin, Ireland, has received timely approval from the World Health Organization (WHO) to initiate offshore manufacturing for its TrinScreen HIV and Uni-Gold HIV diagnostic tests. This development aligns with the company’s Comprehensive Transformation Plan and marks a significant step in enhancing the production capabil...

Shares

Trinity Biotech Shifts into Compliance on Nasdaq Amid Strategic Restructuring

Published Thu, Nov 7 2024 1:20 PM UTC

Trinity Biotech plc, a commercial-stage biotechnology firm with a focus on human diagnostics and diabetes management, has announced a significant regain of compliance with Nasdaq listing requirements. On November 6, 2024, the company received written confirmation from the Nasdaq Stock Market LLC (Nasdaq) that it has successfully met the minimum market value of publicly held ...

Merger and Acquisition

Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer-Focused EpiCapture

Published Fri, Oct 25 2024 12:45 PM UTC

Dublin, Oct. 25, 2024 — In a significant move signaling its ambition to broaden its portfolio, Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company renowned for its innovations in human diagnostics and diabetes management solutions, announced today its acquisition of EpiCapture Limited. EpiCapture, a pioneering firm focused on developing non-invasiv...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.04
Working Capital Ratio 0.25
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 115,224
Net Income per Employee (TTM) -98,358
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.43

Profitability Ratios Current
Gross Margin (MRQ) 38.57 %
Operating Margin (MRQ) -36.06 %
Net Margin (MRQ) -85.36 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Trinity Biotech Plc's Segments
Americas    56.24 % of total Revenue
Ireland    34.26 % of total Revenue
Eliminations    -52.97 % of total Revenue
Asia Africa    35.13 % of total Revenue
Europe including Ireland    8.63 % of total Revenue
Clinical Laboratory Member    72.35 % of total Revenue
Clinical laboratory services    9.15 % of total Revenue
Point-of-Care    18.5 % of total Revenue

  Trinity Biotech Plc Outlook

On May 23 2024 the Trinity Biotech Plc provided following guidance

Trinity Biotech Plc. has announced its financial results for Q1 2024 and has reiterated its guidance for the future. The company stated that they are on track to achieve approximately $20 million of annualized run-rate EBITDASO by Q2 2025, with annualized revenues expected to reach around $75 million by that time.

This projection indicates that Trinity Biotech is confident in its business performance and growth trajectory. By continuing to focus on their strategic goals and objectives, the company aims to reach significant financial milestones within the next year.

Overall, Trinity Biotech's outlook for the future is positive, as they continue to make progress towards their financial targets an...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.